Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (DFPH) Total Debt (2020 - 2025)

Historic Total Debt for Oncology Institute (DFPH) over the last 6 years, with Q3 2025 value amounting to $76.2 million.

  • Oncology Institute's Total Debt fell 1676.04% to $76.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.2 million, marking a year-over-year decrease of 1676.04%. This contributed to the annual value of $93.1 million for FY2024, which is 726.16% up from last year.
  • As of Q3 2025, Oncology Institute's Total Debt stood at $76.2 million, which was down 1676.04% from $75.0 million recorded in Q2 2025.
  • Oncology Institute's 5-year Total Debt high stood at $93.1 million for Q4 2024, and its period low was $183000.0 during Q4 2021.
  • Its 5-year average for Total Debt is $77.6 million, with a median of $82.9 million in 2023.
  • Its Total Debt has fluctuated over the past 5 years, first crashed by 9846.59% in 2021, then surged by 4395519.13% in 2022.
  • Over the past 5 years, Oncology Institute's Total Debt (Quarter) stood at $183000.0 in 2021, then soared by 43955.19% to $80.6 million in 2022, then rose by 7.7% to $86.8 million in 2023, then increased by 7.26% to $93.1 million in 2024, then decreased by 18.19% to $76.2 million in 2025.
  • Its last three reported values are $76.2 million in Q3 2025, $75.0 million for Q2 2025, and $73.9 million during Q1 2025.